Myriad Genetics Inc
$ 7.33
0.00%
04 Dec - close price
- Market Cap 683,257,000 USD
- Current Price $ 7.33
- High / Low $ 7.38 / 7.15
- Stock P/E N/A
- Book Value 4.00
- EPS -4.35
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.72 %
- 52 Week High 16.62
- 52 Week Low 3.76
About
Myriad Genetics, Inc. is a prominent molecular diagnostics firm based in Salt Lake City, Utah, renowned for its innovative genetic testing solutions that support predictive, personalized, and prognostic medicine. The company specializes in key areas such as oncology, hereditary cancer, and reproductive health, empowering healthcare professionals to make data-driven decisions tailored to individual patients. With a strong focus on advancing genetic medicine, Myriad is dedicated to expanding its product offerings and leveraging cutting-edge technology and research to enhance patient outcomes both domestically and internationally, positioning itself as a leader in the evolving landscape of healthcare.
Analyst Target Price
$8.52
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-02-25 | 2024-11-07 | 2024-08-06 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 | 2023-05-03 | 2023-02-28 |
| Reported EPS | -0.2943 | 0.05 | -0.03 | 0.03 | 0.06 | 0.05 | -0.01 | 0.04 | -0.03 | -0.08 | -0.21 | -0.12 |
| Estimated EPS | -0.0132 | -0.01 | -0.0544 | 0.0303 | 0.02 | -0.01 | -0.1 | 0.01 | -0.08 | -0.08 | -0.19 | -0.16 |
| Surprise | -0.2811 | 0.06 | 0.0244 | -0.0003 | 0.04 | 0.06 | 0.09 | 0.03 | 0.05 | 0 | -0.02 | 0.04 |
| Surprise Percentage | -2129.5455% | 600% | 44.8529% | -0.9901% | 200% | 600% | 90% | 300% | 62.5% | 0% | -10.5263% | 25% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0018 |
| Currency | USD |
Previous Dividend Records
| Jan 1970 | |
|---|---|
| Payment Date | None |
| Amount | $1.75 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MYGN
2025-10-15 07:39:25
Janney Montgomery Scott LLC has acquired a new stake in Myriad Genetics, Inc. stock. This article also details other institutional investors who have recently modified their holdings in MYGN, highlighting significant increases in positions by firms like Farther Finance Advisors LLC and GAMMA Investing LLC. The piece also provides an overview of Myriad Genetics, its stock performance, and its genetic testing and precision medicine offerings.
2025-10-14 12:47:24
Myriad Genetics (MYGN) has expanded its Foresight Carrier Screen Universal Plus Panel by adding the F8 and FXN genes, significantly enhancing its diagnostic capabilities for hemophilia A and Friedreich's ataxia. Despite these product advancements and strong institutional ownership, the company faces financial challenges, including negative net margins and an Altman Z-Score indicating potential distress. Its valuation metrics reflect cautious market sentiment, and the company's high stock volatility and sensitivity to market movements present additional risks.
2025-10-14 12:06:36
Myriad Genetics has expanded its Foresight Universal Plus Panel by adding the F8 and FXN genes, which are associated with hemophilia A and Friedreich's ataxia, respectively. This update ensures the Foresight Carrier Screen is fully compliant with American College of Medical Genetics and Genomics recommendations, aiming to provide more comprehensive genetic insights for family planning. The company emphasizes the clinical significance of these additions, continuing its efforts to enhance carrier screening capabilities.
2025-10-14 12:06:36
Myriad Genetics has added the F8 and FXN genes to its Foresight Carrier Screen Universal Plus Panel, making the screen fully compliant with American College of Medical Genetics and Genomics (ACMG) recommendations. The F8 gene is linked to hemophilia A, a hereditary bleeding disorder, while mutations in the FXN gene cause Friedreich's ataxia, a rare, inherited neurodegenerative disease. This expansion aims to provide more comprehensive genetic insights for informed family planning decisions.
2025-10-14 12:00:00
Myriad Genetics (NASDAQ: MYGN) announced on October 14, 2025, that it added the F8 and FXN genes to its Foresight Carrier Screen Universal Plus Panel. This addition makes the Foresight Carrier Screen fully compliant with ACMG recommendations. The F8 gene is linked to hemophilia A, and the FXN gene is linked to Friedreich's ataxia, with all testing processed in Myriad's state-of-the-art facility.
2025-10-13 17:50:11
Inspire Investing LLC has increased its stake in Myriad Genetics, Inc. ($MYGN). Several other institutional investors also adjusted their positions in Myriad Genetics, with a significant portion of the stock owned by hedge funds and institutions. The article also provides an overview of Myriad Genetics' business and recent stock performance.
